Zymedi
PrivateLast Round
Series A
Extension
May 30, 2023
Total Funding Raised
$28.85M
Company Overview
Zymedi operates in Healthcare & Life Sciences and is based in Incheon. Its latest recorded funding round was a Series A Extension round in May 2023.
Zymedi is a biotechnology company that develops a novel therapeutics platform intended to improve the quality of life for people suffering from diseases by focusing on aminoacyl-tRNA synthetases (ARSs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zymedi Comparables
Compare Zymedi with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| aTyr Pharma | 74% | |
| Daewoong Pharmaceutical | 71% | |
| Gossamer Bio | 70% |
For institutional investors. Book with your work email.
Zymedi Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 30, 2023 | ||||
| Series A | Mar 26, 2021 | ||||
| Angel | Oct 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zymedi Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Company K Partners, Limited | Series A, Series A Extension |
| CKD Venture Capital | Series A Extension |
| UTC Investment | Series A, Series A Extension |
| Company K Partners | Series A, Series A Extension |
| Medytox Venture Investment | Series A Extension |
| Korea Development Bank | Series A Extension |
| Korea Venture Investment Corporation | Series A Extension |
For institutional investors. Book with your work email.
Zymedi Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zymedi's valuation, stock price, and market status.
Is Zymedi a public or private company?
Zymedi is a private company.
What is the current stock price of Zymedi?
Zymedi is a private company, so its shares have no public market price. Caplight tracks Zymedi's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zymedi worth (valuation)?
Valuation information for Zymedi is not publicly available.
Can I buy Zymedi stock?
Zymedi shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zymedi's last funding round?
Zymedi's most recent funding round was Series A Extension on May 30, 2023.
Who are the main investors in Zymedi?
Key investors in Zymedi include Company K Partners, Limited, CKD Venture Capital, UTC Investment, Company K Partners, Medytox Venture Investment.
Will Zymedi IPO soon?
No public IPO plans have been announced for Zymedi.
How can I track Zymedi secondary market activity?
Caplight tracks bids, offers, and trades in Zymedi's shares on secondary markets.